Ramucirumab
- Generic Name
- Ramucirumab
- Brand Names
- Cyramza
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 947687-13-0
- Unique Ingredient Identifier
- D99YVK4L0X
- Background
Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and down...
- Indication
Ramucirumab is indicated for the treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel for patients who progress after prior fluoropyrimidine- or platinum-containing chemotherapy. It is indicated, in combination with erlotinib, for the first-line treatment of metastatic no...
- Associated Conditions
- Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Non-Small Cell Lung Cancer, Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Associated Therapies
- -
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 215
- Registration Number
- NCT02791334
- Locations
- 🇪🇸
Hospital Madrid Norte Sanchinarro, Madrid, Spain
🇨🇳National Cheng Kung University Hospital, Tainan, Taiwan
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-06-03
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 29
- Registration Number
- NCT02789345
- Locations
- 🇪🇸
Hospital Universitario Ramon y Cajal, Madrid, Spain
🇨🇳For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei city, Taiwan
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
- Conditions
- Interventions
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 23
- Registration Number
- NCT02745769
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
🇬🇧For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom
Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- Liza Villaruz, MD
- Target Recruit Count
- 7
- Registration Number
- NCT02730247
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2020-01-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT02726399
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-03-17
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 309
- Registration Number
- NCT02711553
- Locations
- 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸UCSF Medical Center at Mission Bay, San Francisco, California, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 924
- Registration Number
- NCT02678182
- Locations
- 🇬🇧
The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Sutton, United Kingdom
Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis
- Conditions
- Interventions
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 62
- Registration Number
- NCT02628951
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 105
- Registration Number
- NCT02597036
- Locations
- 🇺🇸
SMO Sarah Cannon Research Inst., Nashville, Tennessee, United States
🇺🇸Tennessee Oncology PLLC, Nashville, Tennessee, United States
🇪🇸For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain
Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Walid Shaib, MD
- Target Recruit Count
- 84
- Registration Number
- NCT02581215
- Locations
- 🇺🇸
Nebraska Methodist Hospital, Omaha, Nebraska, United States
🇺🇸Gettysburg Cancer Center, Gettysburg, Pennsylvania, United States
🇺🇸Mayo Clinic-Arizona, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.